Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: LT2011 who wrote (11413)	7/6/2012 12:17:36 AM
From: LT2011	Respond to of 13111

Here's our first peek at the new 2012 stock plan as approved by the voters. You have to love Mr. Koe's filing. Read the green lanuage under Explanation of Responses. I still can't find Dr. Wachter's filing and I've looked several times. Please don't tell me he's been cut out of the stock plan. I'm praying that his is being filed late or later. Based on the cut and paste from the 05/14 PVCT press release he is a very important part of the future. Dr. Wachter, age 49, has been with Provectus since 2002, and has served as Executive Vice President-Pharmaceuticals and a Director of the Company since that time. As Chief Technology Officer of Provectus, Dr. Wachter's new position will focus on leading drug development of both PV-10 and PH-10 as well as the intellectual property ("IP") protection of its investigational therapeutic products. With Phase 2 clinical trials for both PV-10 and PH-10 completed, Dr. Wachter will continue spearheading the Company's regulatory efforts, including clinical, nonclinical and manufacturing programs necessary for FDA and international approval and commercialization. Dr. Wachter holds 27 U.S. patents, was a co-founder of Photogen Technologies, where he held several senior management positions, and was also a senior research staff member at the Oak Ridge National Laboratory. He holds a Ph.D. in chemistry from the University of Wisconsin, Madison and a B.S. degree in chemistry from Indiana University-Bloomington. Dr. Dees noted, "As Provectus advances its clinical development programs, Dr. Wachter, in his new position as Chief Technology Officer, will be an instrumental part of our preparation for anticipated Phase 3 clinical testing of PV-10 for metastatic melanoma, as well as our continued development of PH-10." http://www.sec.gov/Archives/edgar/data/315545/000114036112031769/xslF345X03/doc1.xml http://www.sec.gov/Archives/edgar/data/315545/000114036112031766/xslF345X03/doc1.xml http://www.sec.gov/Archives/edgar/data/315545/000114036112031762/xslF345X03/doc1.xml http://www.sec.gov/Archives/edgar/data/315545/000114036112031760/xslF345X03/doc1.xml http://www.sec.gov/Archives/edgar/data/315545/000114036112031759/xslF345X03/doc1.xml